- Home
- TWST vs DNLI Comparison
TWST vs DNLI Comparison
Compare TWST & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWST
- DNLI
- Stock Information
- Founded
- TWST 2013
- DNLI 2013
- Country
- TWST United States
- DNLI United States
- Employees
- TWST N/A
- DNLI N/A
- Industry
- TWST Biotechnology: Biological Products (No Diagnostic Substances)
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TWST Health Care
- DNLI Health Care
- Exchange
- TWST Nasdaq
- DNLI Nasdaq
- Market Cap
- TWST 1.8B
- DNLI 2.1B
- IPO Year
- TWST 2018
- DNLI 2017
- Fundamental
- Price
- TWST $34.64
- DNLI $13.89
- Analyst Decision
- TWST Buy
- DNLI Strong Buy
- Analyst Count
- TWST 10
- DNLI 15
- Target Price
- TWST $49.10
- DNLI $33.85
- AVG Volume (30 Days)
- TWST 1.1M
- DNLI 1.6M
- Earning Date
- TWST 08-01-2025
- DNLI 07-31-2025
- Dividend Yield
- TWST N/A
- DNLI N/A
- EPS Growth
- TWST N/A
- DNLI N/A
- EPS
- TWST N/A
- DNLI N/A
- Revenue
- TWST $347,680,000.00
- DNLI N/A
- Revenue This Year
- TWST $22.58
- DNLI N/A
- Revenue Next Year
- TWST $17.71
- DNLI $335.74
- P/E Ratio
- TWST N/A
- DNLI N/A
- Revenue Growth
- TWST 25.30
- DNLI N/A
- 52 Week Low
- TWST $27.12
- DNLI $10.57
- 52 Week High
- TWST $60.90
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- TWST 55.33
- DNLI 45.02
- Support Level
- TWST $33.41
- DNLI $14.19
- Resistance Level
- TWST $36.39
- DNLI $14.88
- Average True Range (ATR)
- TWST 1.97
- DNLI 0.77
- MACD
- TWST 0.62
- DNLI -0.03
- Stochastic Oscillator
- TWST 75.28
- DNLI 34.55
About TWST Twist Bioscience Corporation
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.